Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 500 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Follow-Up Questions
PHMMF の株価パフォーマンスは？
PHMMF の現在の価格は $93 で、最終取引日から 0% decreased 変動しました。
Pharma Mar SA の主な事業テーマや業界は？
Pharma Mar SA は Biotechnology 業界、セクターは Health Care に属しています。
Pharma Mar SA の時価総額はいくらですか？
Pharma Mar SA の現在の時価総額は $1.5B です。
Pharma Mar SA は、買い、売り、ホールドのどれですか？
ウォール街のアナリスト 10 人の格付けによると、Pharma Mar SA の評価は、強力な買い 1 人、買い 6 人、ホールド 3 人、売り 0 人、強力な売り 1 人です。
